Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine - PubMed (original) (raw)
Comparative Study
. 2001 Jul 16;19(28-29):3981-9.
doi: 10.1016/s0264-410x(01)00129-3.
Affiliations
- PMID: 11427274
- DOI: 10.1016/s0264-410x(01)00129-3
Comparative Study
Immune responses and protection in different strains of aged mice immunized intranasally with an adjuvant-combined influenza vaccine
H Asanuma et al. Vaccine. 2001.
Abstract
Immune responses and protection against influenza virus infection were compared between young (2 months) and aged (18 months) BALB/c, C3H and C57BL/6 (B6) mice after intranasal vaccination. The mice were immunized with 2.5 microg protein of A/PR/8/34 (PR8) (H1N1) virus vaccine containing a cholera toxin adjuvant. In both the young and aged BALB/c mice, high levels of PR8-specific antibody-forming cell (AFC) responses were induced in the nasal-associated lymphoid tissue (NALT) 7 days after immunization. Nasal wash IgA and serum IgG antibody (Ab) responses to the PR8 haemagglutinin (HA) 4 weeks after immunization were slightly higher in the young mice than in the aged mice. The young mice showed complete protection against challenge infection, while the aged mice showed only a partial protection. In the C3H mice, NALT-AFC, and IgA and IgG Ab responses were higher in the young mice than those in the aged mice in parallel with the more efficient protection in the young mice than in the aged mice. Both the young and aged B6 mice showed no NALT-AFC responses, scarce IgA and IgG Ab responses and no protection. In the BALB/c mice, IgG1 and IgG2a levels were significantly lower in the aged mice. On the other hand, in the C3H mice, only IgG2a level was significantly lower in the aged mice. Similar results were obtained in terms of immune responses and protection between the young and aged mice of three different strains of mice after intra-nasal immunization with 0.1 microg of PR8 vaccine containing the adjuvant, two-times at 4-week intervals. In the B6 mice, the immune response was improved by immunization with a higher dose of the adjuvant-combined vaccine. These results suggest that local Ab responses, as well as systemic Ab responses, are downregulated in aged mice, although the degree of the downregulation of immune responses differs from strain to strain.
Similar articles
- Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K).
Watanabe I, Hagiwara Y, Kadowaki SE, Yoshikawa T, Komase K, Aizawa C, Kiyono H, Takeda Y, McGhee JR, Chiba J, Sata T, Kurata T, Tamura S. Watanabe I, et al. Vaccine. 2002 Oct 4;20(29-30):3443-55. doi: 10.1016/s0264-410x(02)00351-1. Vaccine. 2002. PMID: 12297389 - Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines.
Asahi Y, Yoshikawa T, Watanabe I, Iwasaki T, Hasegawa H, Sato Y, Shimada S, Nanno M, Matsuoka Y, Ohwaki M, Iwakura Y, Suzuki Y, Aizawa C, Sata T, Kurata T, Tamura S. Asahi Y, et al. J Immunol. 2002 Mar 15;168(6):2930-8. doi: 10.4049/jimmunol.168.6.2930. J Immunol. 2002. PMID: 11884464 - Protection against influenza virus infection in mice immunized by administration of hemagglutinin-expressing DNAs with electroporation.
Kadowaki S, Chen Z, Asanuma H, Aizawa C, Kurata T, Tamura S. Kadowaki S, et al. Vaccine. 2000 Jun 15;18(25):2779-88. doi: 10.1016/s0264-410x(00)00087-6. Vaccine. 2000. PMID: 10812219 - Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?
Tamura S, Ainai A, Suzuki T, Kurata T, Hasegawa H. Tamura S, et al. Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review. - Mucosal Immune Response in Nasal-Associated Lymphoid Tissue upon Intranasal Administration by Adjuvants.
Takaki H, Ichimiya S, Matsumoto M, Seya T. Takaki H, et al. J Innate Immun. 2018;10(5-6):515-521. doi: 10.1159/000489405. Epub 2018 Jun 1. J Innate Immun. 2018. PMID: 29860261 Free PMC article. Review.
Cited by
- Nano-Encapsulated Antioxidant: Retinoic Acid as a Natural Mucosal Adjuvant for Intranasal Immunization against Chronic Experimental Toxoplasmosis.
Said DE, Amer EI, Sheta E, Makled S, Arafa FM, Diab HE. Said DE, et al. Trop Med Infect Dis. 2023 Feb 7;8(2):106. doi: 10.3390/tropicalmed8020106. Trop Med Infect Dis. 2023. PMID: 36828522 Free PMC article. - Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination.
Reens AL, Cabral DJ, Liang X, Norton JE Jr, Therien AG, Hazuda DJ, Swaminathan G. Reens AL, et al. Front Immunol. 2021 May 13;12:643255. doi: 10.3389/fimmu.2021.643255. eCollection 2021. Front Immunol. 2021. PMID: 34054810 Free PMC article. Review. - Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization.
Sasaki E, Asanuma H, Momose H, Furuhata K, Mizukami T, Hamaguchi I. Sasaki E, et al. Front Immunol. 2020 Sep 11;11:2171. doi: 10.3389/fimmu.2020.02171. eCollection 2020. Front Immunol. 2020. PMID: 33013912 Free PMC article. - The effect of adjuvants on vaccine-induced antibody response against influenza in aged mice.
Concannon MA, Jiang J. Concannon MA, et al. Front Biol (Beijing). 2014;9(2):89-94. doi: 10.1007/s11515-014-1301-7. Epub 2014 Apr 3. Front Biol (Beijing). 2014. PMID: 32215006 Free PMC article. Review. - Influenza Pathogenesis: The Effect of Host Factors on Severity of Disease.
Gounder AP, Boon ACM. Gounder AP, et al. J Immunol. 2019 Jan 15;202(2):341-350. doi: 10.4049/jimmunol.1801010. J Immunol. 2019. PMID: 30617115 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous